TNFRSF4 and Alzheimer disease: Several emerging AD therapies targeting the OX40-OX40L pathway are currently in development, including the monoclonal antibodies rocatinlimab (AMG 451/KHK4083), telazorlimab (ISB 830/GBR 830), and amlitelimab (KY1005/SAR445229) (Figure 6).